PMID- 15735200
OWN - NLM
STAT- MEDLINE
DCOM- 20050630
LR  - 20221207
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 28
IP  - 3
DP  - 2005 Mar
TI  - Effects of pramlintide on postprandial glucose excursions and measures of 
      oxidative stress in patients with type 1 diabetes.
PG  - 632-7
AB  - OBJECTIVE: Oxidative stress has been shown to be increased in the postprandial 
      period in patients with diabetes and has been implicated in the pathogenesis of 
      micro- and macrovascular complications. The aim of this post hoc analysis was to 
      assess the effects of pramlintide, an amylin analog shown to reduce postprandial 
      glucose excursions in patients with diabetes, on markers of oxidative stress in 
      the postprandial period. RESEARCH DESIGN AND METHODS: In a randomized, 
      single-blind, placebo-controlled, crossover study, 18 evaluable subjects with 
      type 1 diabetes underwent two standardized breakfast meal tests and received 
      pramlintide or placebo in addition to their preprandial insulin. The plasma 
      concentrations of glucose and markers of oxidative stress (nitrotyrosine, 
      oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) 
      were measured at baseline and during the 4-h postprandial period. RESULTS: 
      Compared with placebo, pramlintide treatment significantly reduced postprandial 
      excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP 
      (P < 0.03 for all comparisons). Correlation analyses adjusted for treatment 
      revealed a significant association between postprandial mean incremental area 
      under the curve from 0 to 4 h (AUC(0-4 h)) for glucose and postprandial mean 
      incremental AUC(0-4 h) for each measure of oxidative stress (r = 0.75, 0.54, and 
      -0.63 for nitrotyrosine, ox-LDL, and TRAP, respectively; P < 0.001 for all 
      correlations). CONCLUSIONS: These findings indicate that the postprandial 
      glucose-lowering effect of pramlintide in type 1 diabetes is associated with a 
      significant reduction in postprandial oxidative stress.
FAU - Ceriello, Antonio
AU  - Ceriello A
AD  - Department of Pathology and Medicine, Experimental and Clinical, University of 
      Udine, Italy.
FAU - Piconi, Ludovica
AU  - Piconi L
FAU - Quagliaro, Lisa
AU  - Quagliaro L
FAU - Wang, Yan
AU  - Wang Y
FAU - Schnabel, Catherine A
AU  - Schnabel CA
FAU - Ruggles, James A
AU  - Ruggles JA
FAU - Gloster, Maurice A
AU  - Gloster MA
FAU - Maggs, David G
AU  - Maggs DG
FAU - Weyer, Christian
AU  - Weyer C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Amyloid)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Islet Amyloid Polypeptide)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Placebos)
RN  - 0 (oxidized low density lipoprotein)
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
RN  - D3FM8FA78T (pramlintide)
SB  - IM
MH  - Adult
MH  - Amyloid/*therapeutic use
MH  - Blood Glucose/drug effects/*metabolism
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 1/blood/*drug therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Islet Amyloid Polypeptide
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/drug effects/*physiology
MH  - Placebos
MH  - Postprandial Period
MH  - Safety
MH  - Single-Blind Method
MH  - Tyrosine/*analogs & derivatives/*blood
EDAT- 2005/03/01 09:00
MHDA- 2005/07/01 09:00
CRDT- 2005/03/01 09:00
PHST- 2005/03/01 09:00 [pubmed]
PHST- 2005/07/01 09:00 [medline]
PHST- 2005/03/01 09:00 [entrez]
AID - 28/3/632 [pii]
AID - 10.2337/diacare.28.3.632 [doi]
PST - ppublish
SO  - Diabetes Care. 2005 Mar;28(3):632-7. doi: 10.2337/diacare.28.3.632.